Invokana (canagliflozin) is an oral diabetes medication that helps control blood sugar levels. The drug is used together with diet and exercise to treat type 2 diabetes. This medication has been linked to a condition called ketoacidosis, a condition that can cause fatal swelling of the brain, severe dehydration and coma. It may also cause kidney failure and heart attacks.
In 2015 the Food and Drug Administration (FDA) issued a notice warning patients and medical providers about the risks of consuming the drug. In December 2015, the FDA ordered manufacturer to add warning regarding the risk of ketoacidosis and urinary tract infections to the drugs' labels.